8-K - Bluejay Diagnostics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Bluejay Diagnostics issued a corporate update on March 6, 2026, reporting financial results for the year ended December 31, 2025, including $5.2 million in cash and cash equivalents, $6.0 million in stockholders’ equity, and net losses of $6.8 million. The company highlighted progress on its Symphony platform, SYMON II clinical study, manufacturing readiness, and plans to raise at least $20 million in additional capital through 2027.

Key Takeaways

1SYMON II clinical study progressing as planned with ongoing enrollment

2Manufacturing scale-up on track for regulatory submission and commercialization

3Full exercise of prefunded warrants in February 2026 resulted in approximately 972,000 common shares outstanding

4Cash and cash equivalents of $5.2 million as of December 31, 2025

5Stockholders’ equity of $6.0 million as of December 31, 2025

6Net losses of $6.8 million for fiscal year ended December 31, 2025

7Expects to raise at least $20 million through end of 2027 fiscal year

Current Report Details

Event Type

Financial Results

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Financial Results

9.01

. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated March 6, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL

Exhibits Only

Results of Operations

Fiscal Year

Metric	Value	Basis	Prior Period
Net Losses	$6.80

Exhibits (2)

8-K

FORM 8-K

99.1

PRESS RELEASE, DATED MARCH 6, 2026